Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Withdrawn

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma

Interventions: Drug: bendamustine hydrochloride
Biological: rituximab
Drug: obatoclax mesylate

First Posted Date: 2010-11-10

Last Posted Date: 2013-06-06

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01238146

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Phase 2

Completed

Conditions: Diffuse Large B-Cell Lymphoma
Lymphoma, Diffuse Large-Cell
Diffuse Large-Cell Lymphoma
Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2010-11-04

Last Posted Date: 2017-05-24

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT01234467

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
Seby B. Jones Cancer Center, Boone, North Carolina, United States
🇺🇸
Northeast Medical Center, Concord, North Carolina, United States

and more 4 locations

Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Bendamustine
Drug: Rituximab
Radiation: Y-90 ibritumomab

First Posted Date: 2010-11-04

Last Posted Date: 2021-05-18

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 39

Registration Number: NCT01234766

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Maine Center for Cancer Medicine, Scarborough, Maine, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Phase 2

Completed

Conditions: AL Amyloidosis

Interventions: Drug: Bendamustine
Drug: Dexamethasone

First Posted Date: 2010-10-18

Last Posted Date: 2020-03-30

Lead Sponsor: Columbia University

Target Recruit Count: 40

Registration Number: NCT01222260

Locations: 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Columbia University, New York, New York, United States

and more 3 locations

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: TRU-016 and bendamustine
Drug: 20 mg/kg TRU-016 and bendamustine
Drug: 15 mg/kg TRU-016 and bendamustine
Drug: Bendamustine

First Posted Date: 2010-08-25

Last Posted Date: 2021-06-10

Lead Sponsor: Aptevo Therapeutics

Target Recruit Count: 79

Registration Number: NCT01188681

Locations: 🇪🇸
For additional information regarding sites for this trial call (919) 465-4648, Navarre, Spain

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Doxorubicin
Drug: Bortezomib
Drug: Filgrastim

First Posted Date: 2010-08-09

Last Posted Date: 2023-10-06

Lead Sponsor: Sherif Farag, MB, BS

Target Recruit Count: 32

Registration Number: NCT01177683

Locations: 🇺🇸
IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸
Metro Health Cancer Care, Wyoming, Michigan, United States
🇺🇸
Community Regional Cancer Center, Indianapolis, Indiana, United States

and more 4 locations

Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Phase 1

Withdrawn

Conditions: Mantle Cell Lymphoma

First Posted Date: 2010-07-27

Last Posted Date: 2011-03-16

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 20

Registration Number: NCT01170052

Locations: 🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Virchow Klinikum Charité, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Dept. of Hematology and Oncology, Charité, Campus Charité Mitte, Berlin, Germany